Sanofi pays J&J $175M for late-phase E. coli shot, pushing deeper into vaccines as partner retreats

As Johnson & Johnson retreats from the vaccine sector, Sanofi is gambling $175 million on the healthcare giant's late-phase E. coli vaccine.